Table 2A.
Factors | OS at 1 year (%) | OS at 2 years (%) | OS at 5 years (%) | p - value |
---|---|---|---|---|
Age | ||||
65 - 74 years | 61 | 47 | 25 | |
75 – 84 years | 56 | 33 | 4 | |
≥ 85 years | 40 | – | – | 0.08 |
Gender | ||||
Female | 61 | 32 | 13 | |
Male | 57 | 43 | 19 | 0.60 |
ECOG score | ||||
0 - 1 | 63 | 45 | 20 | |
2 - 3 | 33 | 21 | – | 0.001 |
Charlson Comorbidity Index | ||||
≤ 5 | 59 | 40 | 24 | |
> 5 | 57 | 41 | 11 | 0.20 |
Clinical tumor classification (cT) | ||||
1 | 67 | 50 | – | |
2 | 68 | 50 | 9 | |
3 | 56 | 40 | 20 | |
4 | 58 | 37 | 22 | 0.90 |
Clinical lymph node classification (cN) | ||||
Nodal negative (N0) | 48 | 35 | 11 | |
Nodal positive (N+) | 62 | 43 | 21 | 0.10 |
Tumor stage (AJCC) | ||||
1 - 2 | 53 | 36 | 9 | |
3 | 59 | 45 | 20 | |
4a | 63 | 41 | 26 | 0.70 |
Localization of the primary tumor | ||||
0 - 18 cm distance from the incisors (cervical) | 68 | 51 | 24 | |
18 - 24 cm distance from the incisors (upper thoracic third) | 66 | 49 | 25 | |
24 - 32 cm distance from the incisors (middle thoracic third) | 58 | 32 | 11 | |
32 - 40 cm distance from the incisors (lower thoracic third) | 46 | 38 | 22 | 0.60 |
Administration of full-dose RT | ||||
yes | 60 | 42 | 18 | |
no | 28 | 19 | – | 0.01 |
Cumulative dose of RT (EQD2) | ||||
≤ 50 Gy | 57 | 42 | 21 | |
> 50 Gy | 59 | 39 | 14 | 0.90 |
Administration of non-modified, full-dose chemotherapy | ||||
yes | 76 | 58 | 30 | |
no | 43 | 24 | 7 | < 0.001 |
Treatment concept | ||||
Neoadjuvant CRT followed by surgical resection | 71 | 58 | 41 | |
Definitive RT/CRT | 54 | 34 | 9 | 0.002 |
ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer; RT, radiotherapy; EQD2, equivalent dose in 2 Gy fractions; CRT, chemoradiotherapy. Bold values, significant p-values.